[CAS NO. 150821-03-7] Pranlukasthemihydrate
PRODUCTS SPECIFICATIONS [150821-03-7]
DESCRIPTION [150821-03-7]
Overview
| MDL | MFCD00940160 |
|---|---|
| Molecular Weight | 490.51 |
| Molecular Formula | C27H23N5O4.1/2H2O |
| SMILES | O=C(C1=CC=C(OCCCCC2=CC=CC=C2)C=C1)NC3=C4C(C(C=C(C5=NN=NN5)O4)=O)=CC=C3.[1/2].O |
1 Publications Citing Use of MCE
Summary
Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotriene s. Pranlukast inhibits [ 3 H]LTE 4 , [ 3 H]LTD 4 , and [ 3 H]LTC 4 bindings to lung membranes with K i s of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
IC50 & Target
|
LTE 4 0.63 nM (Ki) |
LTD 4 0.99 nM (Ki) |
LTC 4 5640 nM (Ki) |
In Vitro
In the radioligand binding assay, Pranlukast (ONO-1078) inhibits [ 3 H]LTE 4 , [ 3 H]LTD 4 , and [ 3 H]LTC 4 bindings to lung membranes with K i s of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively. The antagonism of Pranlukast against [ 3 H]LTD 4 binding is competitive. In functional experiments, Pranlukast shows competitive antagonism against the LTC 4 - and LTD 4 -induced contractions of guinea pig trachea and lung parenchymal strips with a pA 2 range of 7.70 to 10.71. In the presence of an inhibitor of the bioconversion of LTC 4 to LTD 4 , Pranlukast also antagonizes the LTC 4 -induced contraction of guinea pig trachea (pA 2 =7.78). Pranlukast significantly reverses the LTD 4 -induced prolonged contraction without effect on the KCl- and BaCl 2 -induced contractions of guinea pig trachea [1] . Oxygen-glucose deprivation (OGD)-induced nuclear translocation of CysLT 1 receptors is inhibited by pretreatment with the CysLT 1 receptor antagonist Pranlukast (10 μM). Pranlukast protects endothelial cells against ischemia-like injury. The effects of the CysLT 1 receptor antagonist Pranlukast and the 5-lipoxygenase inhibitor Zileuton on translocation are also assessed. The results show that Pranlukast, but not Zileuton, inhibits the translocation of the CysLT 1 receptor 6 h after OGD [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Carrageenan (CAR, 5 mg per mouse) is injected i.p. 24 h before LPS (50 p,g per mouse) is injected i.v. Various doses of Pranlukast (ONO-1078; 40, 20, and 10 mmol/kg), AA-861 (20, 10, and 5 mmol/kg), Indomethacin (40 mmollkg), and the controls are injected s.c. into mice 30 min before they are challenged with 50 p,g of LPS. The maximum soluble doses are 0.6 mmol/mL in 10% DMSO for AA-861 and 1.2 mmol/mL in 10% ethanol for Pranlukast. These solutions are used as the maximum doses for the treatments. The mortality of mice is significantly decreased in AA-861- Pranlukast-treated mice relative to that in the control mice. Pretreatment with CAR (5 mg i.p.) renders the mice more sensitive to the effect of LPS. Although the survival rate of mice treated with each solvent is 20% at 72 h after LPS (50 p,g per mouse) administration, s.c. treatment with AA-861 (20 mmol/kg) or Pranlukast (40 mmol/kg) significantly increases the survival rate after the LPS administration (AA-861, P<0.001; Pranlukast, P<0.01) [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00127647 | Organon and Co |
Rhinitis, Allergic, Seasonal
|
November 2004 | Phase 3 |
| NCT00410735 | Ono Pharmaceutical Co. Ltd |
Chronic Sinusitis
|
December 2006 | Phase 3 |
| NCT03826485 | SamA Pharmaceutical Co., Ltd |
Healthy
|
April 1, 2019 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 50.97 mM ; Need ultrasonic)
H 2 O : 1 mg/mL ( 2.04 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0387 mL | 10.1935 mL | 20.3869 mL |
| 5 mM | 0.4077 mL | 2.0387 mL | 4.0774 mL |
| 10 mM | 0.2039 mL | 1.0193 mL | 2.0387 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.10 mM); Suspended solution; Need ultrasonic
References
- [1] Obata T, et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol. 1992 Nov;60(3):227-37.
- [2] Fang SH, et al. Nuclear translocation of cysteinyl leukotriene receptor 1 is involved in oxygen-glucose deprivation-induced damage to endothelial cells. Acta Pharmacol Sin. 2012 Dec;33(12):1511-7.
- [3] Ogata M, et al. Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice. Infect Immun. 1992 Jun;60(6):2432-7.
